TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.
Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, Rettig MP, Aldoss I, Advani AS, Godwin J, Wieduwilt MJ, Arellano M, Muth J, Yau TO, Ravandi F, Sweet K, Altmann H, Foulds GA, Stölzel F, Middeke JM, Ciciarello M, Curti A, Valk PJM, Löwenberg B, Gojo I, Bornhäuser M, DiPersio JF, Davidson-Moncada JK, Rutella S.
Vadakekolathu J, et al. Among authors: yau to.
Blood Adv. 2020 Oct 27;4(20):5011-5024. doi: 10.1182/bloodadvances.2020002512.
Blood Adv. 2020.
PMID: 33057635
Free PMC article.